History
1991
Pharmalink and Linc are foundedÂ
1993
Acquisition of Stille AB
1999
The main project in Calliditas is acquired
Listing of Stille AB
2004
New Pharmalink is formed, projects are separated into their own company (current Calliditas Therapeutics) and sales of product portfolio begin
2005
Pharmalink sells product portfolio to Meda
Sedana Medical is founded
2007
Investment in MedCap
2008
Acquisition of shares in nWise AB
2012
Acquisition of shares in Swevet
2013
Investment in Animal Probiotics
2014
Acquisition of shares in Arcoma
2015
Investment in Athera Biotechnologies
2016
Sale of the holding in Meda
Sale of the holding in Bringwell
Sale of the holding in Boule
Investment in Cinclus
2017
Acquisition of shares in Medivir
Listing of Sedana
2018
Listing of Calliditas in Stockholm
Acquisition of shares in Elos
Investment in Index Pharmacuticals
Investment in Sciety
Investment In Gesynta
2019
Founding of Part Production
Sale of the holding in Midsona
2020
Investment in Epicyt
Investment in Synatro
Investment in Fluoguide
Listing of Callidita’s shares in the USA
Investment in Sixera
Investment in OncoZenge
Investment in AdderaCare
Karl Tobieson is appointed CEO and Thomas Bergh CFO of Linc
2021
Sale of the holding in Elos Medtech
Investment in Initiator Pharma
Investment in OssDsign
Investment in Lantmännen Medical
Listing of OncoZenge
Listing of Linc on Nasdaq Stockholm